Nestin, CD133 and ABCG2 are recently discussed as putative markers, co-expression of which might determine a cancer stem cell(CSC) phenotype in sarcomas.
OBJECTIVE:
Our study is focused on immunohistochemical analysis of nestin, CD133 and ABCG2 expression in rhabdomyosarcoma, Ewing sarcoma and osteosarcoma. Furthermore, we also analyzed the possible correlation of nestin, CD133 and ABCG2 expression levels with the patient outcome to identify potential prognostic values of these three putative CSC markers in the same cohorts.
METHODS:
Using immunohistochemistry, expression of nestin, CD133 and ABCG2 was analyzed in 24 rhabdomyosarcoma, 22 Ewing sarcoma and 10 osteosarcoma tissue samples and expression levels of these markers were correlated with clinical outcome.
RESULTS:
High nestin levels indicate poor prognosis in patients with Ewing sarcoma (P = 0.001), and high CD133 expression is associated with shorter survival in rhabdomyosarcoma patients (P = 0.002). In contrast, no significant relationship was found between ABCG2 expression and the clinical outcome.
CONCLUSIONS:
Our analysis represents the first complex study of these three putative CSCs markers together in three different types of pediatric sarcomas and showed their possible prognostic values in these tumors.
PerkinsS.M., ShinoharaE.T., DeWeesT. and FrangoulH., Outcome for children with metastatic solid tumors over the last four decades, PLoS ONE9 (2014), e100396. doi: 10.1371/journal.pone.0100396.
2.
DiestraJ.E., SchefferG.L., CatalaI., MaliepaardM., SchellensJ.H., ScheperR.J., Germà-LluchJ.R. and IzquierdoM.A., Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material, J Pathol198 (2002), 213-219.
3.
GibbsC.P., KukekovV.G., ReithJ.D., TchigrinovaO., SuslovO.N., ScottE.W., GhivizzaniS.C., IgnatovaT.N. and SteindlerD.A., Stem-like cells in bone sarcomas: implications for tumorigenesis, Neoplasia7 (2005), 967-976.
4.
MuraseM., KanoM., TsukaharaT., TakahashiA., TorigoeT., KawaguchiS., KimurS., WadaT., UchihashiY., KondoT., YamashitaT. and SatoN., Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas, Br J Cancer101 (2009), 1425-1432.
5.
SuvaM.L., RiggiN., StehleJ.C., BaumerK., TercierS., JosephJ.M., SuvaD., ClementV., ProveroP., CironiL., OsterheldM.C., GuillouL. and StamenkovicI., Identification of cancer stem cells in Ewing's sarcoma, Cancer Res69 (2009), 1776-1781.
6.
AdhikariA.S., AgarwalN., WoodB.M., PorrettaC., RuizB., PochampallyR.R. and IwakumbaT., CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance, Cancer Res70 (2010), 4602-4612.
7.
TerryJ. and NielsenT., Expression of CD133 in synovial sarcoma, Appl Immunohistochem Mol Morphol18 (2010), 159-165.
8.
SanaJ., ZamboI., SkodaJ., NeradilJ., ChlapekP., HermanovaM., MudryP., VasikovaA., ZitterbartK., HamplA., SterbaJ. and VeselskaR., CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines, Anal Cell Pathol34 (2011), 303-318.
9.
HockfieldS. and McKayR.D., Identification of major cell classes in the developing mammalian nervous system, J Neurosci5 (1985), 3310-3328.
10.
LendahlU., ZimmermanL.B. and McKayR.D., CNS stem cells express a new class of intermediate filament protein, Cell60 (1990), 585-595.
11.
Krupkova JrO., LojaT., ZamboI. and VeselskaR., Nestin expression in human tumors and tumor cell lines, Neoplasma57 (2010), 291-298.
12.
NeradilJ. and VeselskaR., Nestin as a marker of cancer stem cells, Cancer Sci106 (2015), 803-811.
13.
IshiwataT., MatsudaY. and NaitoZ., Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis, World J Gastroenterol17 (2011), 409-418.
14.
SadikovicB., GrahamC., HoM., ZielenskaM. and SomersG.R., Immunohistochemical expression and cluster analysis of mesenchymal and neural stem cell-associated proteins in pediatric soft tissue sarcomas, Pediatr Dev Pathol14 (2011), 259-272.
15.
GlumacS., PejicS., KovacevicR., DunjerovicD., DavidovicR., RisticD. and SoptaJ., Immunohistochemical expression of nestin in rhabdomyosarcoma: implications for clinicopathology and patient outcome, Genet Mol Res14 (2015), 14649-14659.
16.
VeselskaR., HermanovaM., LojaT., ChlapekP., ZamboI., VeselyK., ZitterbartK. and SterbaJ., Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines, BMC Cancer8 (2008), 300. doi: 10.1186/1471-2407-8-300.
17.
ZamboI., HermanovaM., KrakorovaD.A., MudryP., ZitterbartK., KyrM., VeselyK., SterbaJ. and VeselskaR., Nestin expression in high-grade osteosarcomas and its clinical significance, Oncol Rep27 (2012), 1592-1598.
18.
EhrmannJ., KolarZ. and MokryJ., Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumors, J Clin Pathol58 (2014), 222-223.
19.
KolarZ., EhrmannJ., Jr, TurashviliG., BouchalJ. and MokryJ., A novel myoepithelial/progenitor cell marker in the breast? Virchow Arch450 (2007), 607-609.
20.
HeQ.Z., LuoX.Z., ZhouQ., WangK., LiS.X., LiY., ZhuH.T. and DuanT., Expression of nestin in ovarian serous cancer and its clinicopathological significance, Eur Rev Med Pharmacol Sci17 (2013), 2896-2901.
21.
SabetM.N., RakhshanA., ErfaniE. and MadjdZ., Co-expression of putative cancer stem cell markers, CD133 and nestin, in skin tumors, Asian Pac J Cancer Prev15 (2014), 8161-8169.
22.
SvachovaH., KryukovF., KryukovaE., S Sevcikova, NemecP., GreslikovaH., RihovaL., KubiczkovaL. and HajekR., Nestin expression throughout multistep pathogenesis of multiple myeloma, Br J Haematol164 (2014), 701-709.
23.
MiragliaS., GodfreyW., YinA.H., AtkinsK., WarnkeR., HoldenJ.T., BrayR.A., WallerE.K. and BuckD.W., A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning, Blood90 (1997), 5013-5021.
24.
YinA.H., MiragliaS., ZanjaniE.D., Almeida-PoradaG., OgawaM., LearyA.G., OlweusJ., KearneyJ. and BuckD.W., AC133, a novel marker for human hematopoietic stem and progenitor cells, Blood90 (1997), 5002-5012.
25.
WeigmannA., CorbeilD., HellwigA. and HuttnerW.B., Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells, Proc Natl Acad Sci U S A94 (1997), 12425-12430.
26.
MarzescoA.M., JanichP., Wilsch-BräuningerM., DubreuilV., LangenfeldK., CorbeilD. and HuttnerW.B., Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells, J Cell Sci118 (2005), 2849-2858.
27.
DubreuilV., MarzescoA.M., CorbeilD., HuttnerW.B. and Wilsch-BräuningerM., Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1, J Cell Biol176 (2007), 483-495.
28.
ZobalovaR., McDermottL., StanticM., ProkopovaK., DongL.F. and NeuzilJ., CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP, Biochem Biophys Res Commun373 (2008), 567-571.
29.
WuchterC., RateiR., SpahnG., SchochC., HarbottJ., SchnittgerS., HaferlachT., CreutzigU., SperlingC., KarawajewL. and LudwigW.D., Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping, Haematologica86 (2001), 154-161.
30.
Grosse-GehlingP., FergeasC.A., DittfeldC., GarbeY., AlisonM.R., CorbeilD. and Kunz-SchughartL.A., CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges, J Pathol229 (2013), 355-378.
31.
HeA., QiW., HuangY., FengT., ChenJ., SunY., ShenZ. and YaoY., CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study, Exp Ther Med4 (2012), 435-441.
32.
LiJ., ZhongX.Y., LiZ.Y., CaiJ.F., ZouL., LiJ.M., YangT. and LiuW., CD133 expression in osteosarcoma and derivation of CD133+ cells, Mol Med Rep7 (2013), 577-584.
33.
TirinoV., DesiderioV., PainF., De RosaA., PapaccioF., FazioliF., PirozziG. and PapaccioG., Human primary bone sarcomas contain CD133+ displaying high tumorigenicity in vivo, FASEB J25 (2011), 2022-2030.
34.
WalterD., SatheeshaS., AlbrechtP., BornhauserB.C., D'AlessandroV., OeschS.M., RehrauerH., LeuschnerI., KoscielniakE., GenglerC., MochH., BernasconiM., NiggliF.K. and SchäferB.W., CWS Study Group, CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres, PLoS ONE6 (2011), e19506. doi: 10.1371/journal.pone0019506.
DeanM., ABC transporters, drug resistance, and cancer stem cells, J Mammary Gland Biol Neoplasia14 (2009), 3-9.
37.
LiuH.G., PanY.F., YouJ., WangO.C., HuangK.T. and ZhangX.H., Expression of ABCG2 and its significance in colorectal cancer, Asian Pac J Cancer Prev11 (2010), 845-848.
38.
CotterillS.J., AhrensS., PaulussenM., JürgensH.F., VoûteP.A., GadnerH. and CraftA.W., Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group, J Clin Oncol18 (2000), 3108-3114.
39.
LadensteinR., PötschgerU., Le DeleyM.C., WhelanJ., PaulussenM., OberlinO., BergH. van den, DirksenU., HjorthL., MichonJ., LewisI., CraftA. and JürgensH., Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial, J Clin Oncol28 (2010), 3284-3291.
40.
BrenemanJ.C., LydenE., PappoA.S., LinkM.P., AndersonJ.R., ParhamD.M., QualmanS.J., WharamM.D., DonaldsonS.S., MaurerH.M., MeyerW.H., BakerK.S., NC., Paidas and CristW.M., Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV, J Clin Oncol21 (2003), 78-84.
41.
BacciG., ForniC., LonghiA., FerrariS., MercuriM., BertoniF., SerraM., BriccoliA., BalladelliA. and PicciP., Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution, J Surg Oncol96 (2007), 118-123.
42.
WuC., WeiQ., UtomoV., NadesanP., WhetstoneH., KandelR., WunderJ.S. and AlmanB.A., Side population cells isolated from mesenchymal neoplasms have tumor initiating potential, Cancer Res67 (2007), 8216-8222.
43.
GaoN., XuH., LiuC., XuH., ChenG., WangX., LiY. and WangY., Nestin: predicting specific survival factors for breast cancer, Tumor Biol35 (2014), 1751-1755.
44.
NambirajanA., SharmaM.C., GuptaR.K., SuriV., SinghM. and SarkarC., Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas, Neuropathol Appl Neurobiol40 (2014), 714-7125.
45.
KobayashiM., SjöbergG., SöderhällS., LendahlU., SandstedtB. and SejersenT., Pediatric rhabdomyosarcomas express the intermediate filament nestin, Pediatric Research43 (1998), 386-392.
46.
KachinskyA., DominovJ. and MillerJ., Myogenesis and the intermediate filament nestin, Dev Biol165 (1994), 216-228.
47.
SjöbergG., EdströmL., LendahlU. and SejrsenT., Myofibres from Duchenne/Becker muscular dystrophy and myositis express the intermediate filament nestin, J Neuropathol Exp Neurol53 (1994), 416-423.
48.
VaittinenS., LukkaR., SahlgrenC., HurmeT., RantanenJ., LendahlU., ErikssonJ.E. and KalimoH., The expression of intermediate filament protein nestin as related to vimentin and desmin in regenerating skeletal muscle, J Neuropathol Exp Neurol60 (2001), 588-597.
49.
PalliniR., Ricci-VitianiL., BannaG.L., SignoreM., LombardiD., TodaroM., StassiG., MartiniM., MariaG., LaroccaL.M. and De MariaR., Cancer stem cell analysis and clinical outcome in patients with glioblastoma mutliforme, Clin Cancer Res14 (2008), 8205-8212.
50.
RasoA., MascelliS., BiassoniR., NozzaP., KoolM., PistorioA., UgolottiE., MilanaccioC., PignatelliS., FerraroM., PavanelloM., RavegnariM., CamaA., GarreM.L. and CapraV., High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma, Neuro Oncol13 (2011), 500-508.
51.
XiH.Q. and ZhaoP., Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma, J Clin Pathol64 (2011), 498-503.
52.
TakahashiS., KamiyamaT., TomaruU., IshizuA., ShidaT., OsakaM., SatoY., SajiY., OzakiM. and TodoS., Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients, Oncol Rep24 (2010), 1201-1212.
53.
KojimaM., IshiiG., AtsumiN., FujiiS., SaitoN. and OchiaiA., Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study, Cancer Sci99 (2008), 1578-1583.
54.
ZhaoP., LuY., JiangX. and LiX., Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma, Cancer Sci102 (2011), 1107-1111.
55.
SasakiA., KamiyamaT., YokooH., NakanishiK., KubotaK., HagaH., MatsushitaM., OzakiM., MatsunoY. and TodoS., Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma, Oncol Rep24 (2010), 537-546.
56.
ZhangJ., GuoX., ChangD.Y., RosenD.G., Mercado-UribeI. and LiuJ., CD133 expression associated with poor prognosis in ovarian cancer, Mod Pathol25 (2012), 456-464.
57.
MaedaS., ShinchiH., KuraharaH., MatakiY., MaemuraK., SatoM., NatsugoeS., AikouT. and TakaoS., CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer, Br J Cancer22 (2008), 1389-1397.
58.
ZhaoP., LiY. and LuY., Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma, BMC Cancer10 (2010), 218. doi: 10.1186/1471-2407-10-218.
59.
TakenobuH., ShimozatoO., NakamuraT., OchiaiH., YamaguchiY., OhiraM., NakagawaraA. and KamijoT., CD133 suppresses neuroblastoma cell differentiation via signal pathway modification, Oncogene30 (2011), 97-105.
60.
MakA.B., NixonA.M., KittanakomS., StewartJ.M., ChenG.I., CurakJ., GingrasA.C., MazitschekR., NeelB.G., StagljarI. and MoffatJ., Regulation of CD133 by HDAC6 promotes β -catenin signaling to suppress cancer cell differentiation, Cell Rep2 (2012), 951-963.
61.
WeiY., JiangY., ZouF., LiuY., WangS., XuN., XuN., CuiC., XingY., LiuY., CaoB., LiuC., WuG., AoH., ZhangX. and JiangJ., Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells, Proc Natl Acad Sci USA110 (2013), 6829-6834.
NunukovaA., NeradilJ., SkodaJ., JarosJ., HamplA., SterbaJ. and VeselskaR., Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines, Int J Mol Med36 (2015), 65-72.
64.
HuangM., ZhuH., FengJ., NiS. and HuangJ., High CD133 Expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer, Dis Markers (2015), Article ID: 986095. doi: 10.1155/2015/986095.
65.
SkodaJ., NunukovaA., LojaT., ZamboI., NeradilJ., MudryP., ZitterbartK., HermanovaM., HamplA., SterbaJ. and VeselskaR., Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice, Tumor Biol (2016), doi: 10.1007/s13277-016-4837-0.
66.
RossD.D., KarpJ.E., ChenT.T. and DoyleL.A., Expression of breast cancer resistance protein in blast cells from patients with acute leukemia, Blood96 (2000), 365-368.
67.
PlasschaertS.L., KolkD.M. van der, de BontE.S., KampsW.A., MorisakiK., BatesS.E., SchefferG.L., ScheperR.J., VellengaE. and de VriesE.G., The role of breast cancer resistance protein in acute lymphoblastic leukemia, Clin Cancer Res9 (2003), 5171-5177.
68.
SaglamA., HayranM. and UnerA.H., Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas, APMIS116 (2008), 791-800.
69.
YohK., IshiiG., YokoseT., MinegishiY., TsutaK., GotoK., NishiwakiY., KodamaT., SugaM. and OchiaiA., Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer, Clin Cancer Res10 (2004), 1691-1697.
70.
OtaS., IshiiG., GotoK., KubotaK., KimY.H., KojikaM., MurataY., YamazakiM., NishiwakiY., EguchiK. and OchiaiA., Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced nonsmall-cell lung cancer treated with cisplatinbased chemotherapy, Lung Cancer64 (2009), 98-104.
71.
KimY.H., IshiiG., GotoK., OtaS., KubotaK., MurataY., MishimaM., SaijoN., NishiwakiY. and OchiaiA., Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer, Lung Cancer65 (2009), 105-111.
72.
TirinoV., DesiderioV., d'AquinoR., De FrancescoF., PirozziG., GrazianoA., GalderisiU., CavaliereC., De RosaA., PapaccioG. and GiordanoA., Detection and characterization of CD133+$ cancer stem cells in human solid tumours, PLoS ONE3 (2008), e3469. doi: 10.1371/journal.pone.0003469.
